Latest 3 stories · newest Oct 1, 2026
Japan's MHLW approved Novocure's Optune Pax for unresectable, locally advanced pancreatic cancer, delivering a significant milestone for the company's therapy platform.
Novocure's Optune Pax device received a CE Mark for locally advanced pancreatic cancer supported by significant overall survival improvements in the PANOVA-3 trial. This regulatory milestone expands the device's market reach and addresses the critical need for effective therapies in pancreatic cance…
NovoCure announced topline results from its Phase 3 TRIDENT trial evaluating earlier initiation of Tumor Treating Fields therapy in newly diagnosed glioblastoma, which failed to meet its primary endpoint of demonstrating statistically significant overall survival improvement. The trial showed no new…
The same NVCR feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/NVCR/newsSTART FREE